Company Overview

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disease characterized by recurrent and potentially life-threatening swelling attacks. The company operates within the biotechnology and rare disease therapeutics industries, with its primary focus centered on small-molecule bradykinin B2 receptor antagonists designed to prevent and treat HAE attacks. Pharvaris’ lead programs include deucrictibant formulations for both on-demand and prophylactic use, which represent the company’s primary development and value drivers based on public filings and clinical disclosures.

The company was founded in 2015 by former executives and scientists associated with HAE-focused pharmaceutical development efforts, including individuals previously connected to Shire and related rare disease programs. Pharvaris established its corporate headquarters in Zug, Switzerland, and later listed on Nasdaq under the ticker PHVS. Its strategic positioning is tied to the development of orally administered therapies intended to offer an alternative to injectable HAE treatments currently used in the market. Publicly available company disclosures and industry reporting indicate that Pharvaris seeks differentiation through patient convenience, rapid administration, and lifecycle expansion across acute and preventive treatment settings.

Business Operations

Pharvaris primarily operates through a single biotechnology development platform focused on HAE therapeutics. Its principal business activities involve clinical research, regulatory development, intellectual property management, and advancement of its deucrictibant-based product candidates. The company’s key programs include PHVS416 for on-demand treatment and PHVS719 for prophylactic prevention of HAE attacks. Revenue generation has not yet been established through commercial product sales, as the company remains in the clinical development stage according to public regulatory filings and investor communications.

Operationally, Pharvaris conducts activities across North America and Europe, utilizing external contract research organizations, manufacturing partners, and clinical trial networks to support development programs. The company maintains proprietary rights surrounding its oral bradykinin B2 receptor antagonist platform and has reported collaborations with third-party manufacturers and research providers necessary for drug development and clinical supply. Data regarding large-scale joint ventures or diversified subsidiary structures remains limited in publicly available disclosures, and no major revenue-generating subsidiaries have been publicly identified as of available filings.

Strategic Position & Investments

Pharvaris’ strategic direction centers on expanding oral treatment options within the HAE market, where injectable biologics and peptide-based therapies have historically dominated treatment paradigms. The company’s growth initiatives are primarily focused on advancing late-stage clinical development, pursuing regulatory approvals in major pharmaceutical markets, and potentially expanding deucrictibant applications across both acute and preventive care settings. Public filings and corporate presentations indicate that management views oral administration as a key differentiator capable of improving treatment accessibility and patient adherence.

The company has invested significantly in clinical trials, formulation technologies, and intellectual property surrounding deucrictibant. Pharvaris has also focused on strengthening its balance sheet through public equity financing and capital market activity following its Nasdaq listing. Available public information does not indicate major acquisition activity or extensive portfolio-company ownership. Its strategic emphasis remains concentrated on rare disease therapeutics and the advancement of internally developed assets rather than diversified pharmaceutical expansion.

Geographic Footprint

Pharvaris is headquartered in Zug, Switzerland, with operational and clinical activities extending across Europe, the United States, and additional international research jurisdictions involved in HAE clinical studies. The company maintains a strong presence in the U.S. biotechnology capital markets through its Nasdaq listing and conducts substantial clinical and regulatory engagement with U.S. healthcare authorities and trial sites.

Its clinical development footprint includes multinational trial participation intended to support future regulatory submissions in key pharmaceutical markets. Public disclosures indicate operational influence primarily within developed healthcare markets where rare disease therapeutics reimbursement frameworks are established, including regions within North America and Europe. Data regarding substantial commercial infrastructure outside these regions remains inconclusive based on available public sources.

Leadership & Governance

Pharvaris was founded by executives and researchers with prior experience in rare disease and HAE-focused pharmaceutical development. The company’s leadership strategy has emphasized accelerated clinical execution, differentiated oral therapeutics, and disciplined capital allocation typical of development-stage biotechnology companies. Corporate governance disclosures indicate oversight through an independent board structure consistent with Nasdaq-listed biotechnology firms.

Key executives include:

• Berndt Modig – Chief Executive Officer
• Sijmen de Vries – Chairman of the Board
• Jennifer Buell – Chief Operating Officer
• Fabrice Chouraqui – Board Member
• Craig Johnson – Chief Financial Officer

Public statements from company leadership consistently emphasize expanding treatment flexibility for HAE patients, advancing oral therapeutic innovation, and building a focused rare disease biotechnology platform through clinical execution and regulatory progression.